Search

Your search keyword '"Diaz, Rafael"' showing total 1,189 results

Search Constraints

Start Over You searched for: Author "Diaz, Rafael" Remove constraint Author: "Diaz, Rafael" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
1,189 results on '"Diaz, Rafael"'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2. Continuous Analogues for the Pochhammer Symbol

3. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

4. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.

5. Financialization of the Real Estate Market in Spain

6. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

7. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

8. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

9. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk

10. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial

12. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study

13. Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case–control study

14. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial

19. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF

21. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.

23. Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT

25. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome

26. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.

27. Impact of Complete Revascularization in the ISCHEMIA Trial

30. Abstract 13567: Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

32. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

33. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

34. The Pristine Survey -- VI. The first three years of medium-resolution follow-up spectroscopy of Pristine EMP star candidates

35. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

36. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

37. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

40. Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

41. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

42. Indirect Influences, Links Ranking, and Deconstruction of Networks

43. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

44. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

46. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

47. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

48. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study

Catalog

Books, media, physical & digital resources